- Home
- ANL vs ATNM Comparison
ANL vs ATNM Comparison
Compare ANL & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANL | ATNM |
|---|---|---|
| Founded | 2004 | 2000 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 325.5M | 36.8M |
| IPO Year | 2022 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ANL | ATNM |
|---|---|---|
| Price | $7.95 | $1.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $16.00 | $4.00 |
| AVG Volume (30 Days) | ★ 215.2K | 104.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.60 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $1.02 |
| 52 Week High | $12.09 | $1.95 |
Technical Indicators
Market Signals| Indicator | ANL | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 47.12 | 43.37 |
| Support Level | $7.21 | $1.02 |
| Resistance Level | $9.98 | $1.25 |
| Average True Range (ATR) | 1.05 | 0.07 |
| MACD | -0.31 | 0.01 |
| Stochastic Oscillator | 25.68 | 38.74 |
Price Performance
Historical ComparisonAbout ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.